Targovax – Therapeutic cancer vaccines

Advancing immunotherapy vaccines for patients with RAS-mutated cancers

Targovax is a Norwegian-based global biotechnology company, dedicated to the design and development of immunotherapy vaccines for patients with RAS-mutated cancers.

Read more

Each vaccine is designed to harness the patient’s own immune system to fight the cancer while also delivering a favourable safety and tolerability profile.

Read more

Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology and contemplate a private placement of NOK 125–150 million to fund the combined business.

Read more